Dupilumab treatment in patients with chronic rhinosinusitis with nasal polyps: the effect on comorbid eosinophilic otitis media

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-508068-31-00

Enrollment

Registered

2024-08-19

Start date

2024-09-11

Completion date

Unknown

Last updated

2024-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic rhinosinusitis with nasal polyps, eosinophilic otitis media

Brief summary

Change of questionnaire scores between baseline and 6 or 12 months of treatment in CRSwNP+EOM patients

Detailed description

Change of audiometry outcomes between baseline and 6 or 12 months of treatment, Change of questionnaire scores between baseline and 1, 3, 6 and 12 months of treatment, Change of otoscopic findings between baseline and 1, 3, 6 and 12 months of treatment

Interventions

DRUGDupixent 300 mg solution for injection in pre-filled pen

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Change of questionnaire scores between baseline and 6 or 12 months of treatment in CRSwNP+EOM patients	—

Secondary

Measure	Time frame
Change of audiometry outcomes between baseline and 6 or 12 months of treatment, Change of questionnaire scores between baseline and 1, 3, 6 and 12 months of treatment, Change of otoscopic findings between baseline and 1, 3, 6 and 12 months of treatment	—

Countries

Netherlands

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026